Dr Reddy’s Laboratories has reported a consolidated net profit of Rs 570.8 crore in the first quarter of FY22, a 1.5 per cent dip on a year-on-year basis. In comparison, revenue from operations grew by 11.4 per cent to Rs 4,919.4 crore during the quarter.
Dr Reddy’s said it had received a subpoena (written order to attend court to give evidence) from the American market regulator Securities and Exchange Commission (SEC) for producing documents concerning the Commonwealth of Independent States (CIS) geographies.
The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22 and the US market regulator’s subpoena on documents for CIS geographies.
- Waaree Energies shares Surge 3% on Plans to Acquire Enel Green Power
- Stocks in Focus: Macrotech Developers, Vodafone Idea, Avenue Supermarts, and Others
- Stocks Under F&O Ban: Hindustan Copper, RBL Bank, and Others
- Choosing the best demat account in 2025
- People’s Bank of China Stops Bond Buying
Kunal Randeria of Edelweiss Securities said the disappointing numbers, the big margin miss, and the subpoena by the US SEC following an investigation into practices in Ukraine were the reasons behind the stock fall.
Stock Covered in the news
